Satellos asks FDA to clear Phase 2 trial of DMD treatment
Satellos Bioscience asked the U.S. Food and Drug Administration (FDA) for clearance to conduct a Phase 2 clinical trial testing SAT-3247 in children with Duchenne muscular dystrophy (DMD) who are able to walk. The three-month study will randomly assign participants to SAT-324, taken as a pill, or a placebo.